ClinicalTrials.Veeva

Menu
S

South Texas Accelerated Research Therapeutics | START Mountain Region

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SM08502
SL-172154
AB801
LP-184
Osimertinib
LP-284
ADRX-0405
REC-1245
Abiraterone Acetate
FMC-376

Parent organization

This site is a part of South Texas Accelerated Research Therapeutics

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

32 of 39 total trials

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

This study will evaluate the preliminary efficacy of IMP1734 in patients with recurrent advanced/metastatic breast cancer, ovarian cancer and metasta...

Enrolling
Advanced Solid Tumor
Drug: IMP1734

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study, designed to evaluate safety and preliminary efficacy of IA...

Enrolling
HER2 Mutation-Related Tumors
Drug: Trastuzumab
Drug: IAM1363

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants w...

Enrolling
Solid Tumor
Drug: Cemiplimab
Drug: BHV-1510

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will...

Enrolling
Advanced Solid Tumors with KRAS G12C Mutations
Solid Tumor, Adult
Drug: FMC-376
Recently updated

The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a re...

Enrolling
Advanced Cancer
Drug: Docetaxel
Drug: Zimberelimab

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0405 in patie...

Enrolling
Solid Tumors
Drug: ADRX-0405
Locations recently updated

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patie...

Enrolling
Triple Negative Breast Cancer (TNBC)
Urothelial Cancer
Drug: ADRX-0706

The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in part...

Enrolling
Advanced Solid Tumors
Drug: Capecitabine
Drug: Docetaxel

The purpose of this study is to determine the relative bioavailability (rBA; Period 1) and bioequivalence (BE; Period 2 and 3) of various strengths a...

Active, not recruiting
Prostatic Neoplasms
Drug: Niraparib
Drug: Abiraterone Acetate (AA)

The purpose of this study is to determine whether the amount of time before disease progression can be prolonged in participants with metastatic cast...

Enrolling
Inhibitory Checkpoint Molecule
Immunotherapy
Drug: docetaxel
Drug: Prednisone

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metast...

Enrolling
Esophageal Cancer
Advanced Solid Tumor
Drug: LY4052031
Locations recently updated

The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumo...

Enrolling
Uterine Cervical Neoplasms
Ovarian Neoplasms
Drug: LY4170156
Locations recently updated

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in parti...

Enrolling
Small-cell Lung Cancer
Melanoma
Biological: MGC026 Dose for Expansion
Biological: MGC026 Dose Escalation

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.

Enrolling
Endometrial Cancer
Breast Cancer
Drug: Pembrolizumab
Drug: IDE-161

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of...

Enrolling
Carcinoma, Non-Small-Cell Lung
Pancreatic Ductal Adenocarcinoma
Drug: PF-08046050

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of...

Enrolling
Endometrial
Other Solid Tumors
Drug: PF-08052666

This is a multi-center, open-label study to investigate the safety, tolerability, PK, PD, and preliminary activity of REC-1245 administered orally on...

Enrolling
Locally Advanced
Metastatic Cancers
Drug: REC-1245

Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal...

Enrolling
Breast Cancer
Melanoma
Drug: Cemiplimab
Drug: SNS-101 (anti-VISTA)
Locations recently updated

Genes contain genetic code which tell the body which proteins to make. Some types of cancer are caused by changes, or mutations, in a gene called KRA...

Enrolling
Solid Tumor
Drug: ASP4396

The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if...

Enrolling
Breast Cancer
Drug: vepdegestrant
Drug: PF-07220060

Trial sponsors

Lilly logo
Seagen logo
A
B
Genmab logo
L
MacroGenics logo
A
Arcus Biosciences logo
Astellas logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems